NervGen Pharma
Vancouver
About NervGen Pharma
NervGen Pharma is a medicine company dedicated to creating solutions for the treatment of nerve damage and neurodegenerative diseases. The company's lead compound, NVG-291, has placed ahead for both spinal cord injury and multiple sclerosis. The company plans to initiate a Phase 1 human clinical trial on healthy subjects in early 2020 with an expansion of the trial in the second half of 2020 to include a cohort of spinal cord injury patients. In addition, the company intends to commence a Phase 2 multiple sclerosis clinical trial in early 2021.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $62.0M
- Funding stage: IPO
- Last round: Post-IPO Equity (Nov 2025)
- Ticker: cve:NGEN
- Website: nervgen.com
- Phone: 6047225361
Industries & Categories
Biotechnology, Medical, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/nervgen-pharma-76038 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.